TechConnect Innovation Program

Meros drug and biologic delivery polymers

Meros Polymers Inc., AB, Canada

TECHNOLOGY SUMMARY

Meros drug delivery polymers provide enhanced solubility, stability and sustained release of pharmaceuticals for multiple routes of administration. Bio-compatible and biodegradable, the polymers self-assemble into drug-loaded micelles, which can be further processed by lyophilisation or spray-drying, suitable for formulation using conventional methods and facilities.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 6

FIGURES OF MERIT

Value Proposition: Meros technology combines highly effective solubilization, active targeting, sustained circulation by evading liver and kidney uptake, and local or systemic delivery. Our patented polymers accommodate a wide range of biological actives from small molecules to oligonucleotides and provide safe, highly targeted delivery to diseased cells, sparing healthy tissue.

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Global Innovation Awardee

Showcase Booth #: 28T

Website: www.merospolymers.com

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date: This technology was developed at the University of Alberta and has been extensively funded by Canadian federal granting agencies including the National Sciences and Engineering Research Council, the Canadian Institutes of Health Research and the former Alberta Heritage Foundation for Medical Research.

Meros Polymers was formed in 2010 to commercialize the technology and has licensed exclusive rights from the University of Alberta. Since its formation, Meros has been awarded two Alberta Innovation vouchers ($15,000 and $50,000.

Recent Canadian and Alberta government funding to Meros includes:

2013 – Canada National Research Council Industrial Research Assistance Program (IRAP); $50k awarded for technical and business development personnel support.

2013 - Alberta Innovates – Technology Futures (AITF) Joint Development Initiative grant; $102k awarded for GLP preclinical safety testing.

Primary Sources of Funding: Angel, Friends, Family, Federal Grant

Looking for: Both Funding and Development Partners